葵花药业(002737) - 2023 Q3 - 季度财报

Financial Performance - The company's operating revenue for the third quarter reached ¥1,201,272,925.18, an increase of 22.54% compared to the same period last year[4]. - Net profit attributable to shareholders was ¥213,026,370.54, reflecting a significant increase of 97.52% year-on-year[4]. - The net profit after deducting non-recurring gains and losses was ¥210,221,918.08, up 108.47% from the previous year[4]. - Basic earnings per share rose to ¥0.37, a 94.74% increase compared to the same period last year[4]. - The company experienced a 31.14% increase in operating income year-to-date, totaling ¥4,235,195,578.94[7]. - Net profit attributable to shareholders for Q3 2023 was CNY 676,274,677.32, representing a growth of 45.2% year-on-year[25]. - The net profit for the current period is approximately ¥887.06 million, a significant increase of 65.2% compared to ¥536.81 million in the previous period[26]. - The total comprehensive income attributable to the parent company's owners is approximately ¥851.20 million, up from ¥508.97 million, reflecting a growth of 67.2%[27]. - Basic earnings per share increased to ¥1.47, compared to ¥0.88 in the previous period, representing a growth of 67.0%[27]. - The operating profit for the current period is approximately ¥1.04 billion, compared to ¥676.12 million in the previous period, indicating an increase of 54.2%[26]. Assets and Liabilities - Total assets at the end of the reporting period were ¥6,344,984,520.59, a decrease of 9.77% from the end of the previous year[4]. - The company's total assets as of the end of Q3 2023 were CNY 6,344,984,520.59, a decrease from CNY 7,031,765,675.45 at the end of Q2 2023[25]. - The total assets decreased to approximately ¥6.34 billion from ¥7.03 billion, a decline of 9.8%[34]. - The total liabilities decreased to approximately ¥1.62 billion from ¥2.59 billion, a reduction of 37.5%[34]. - The company's total equity attributable to shareholders increased to ¥4,489,108,733.90, a growth of 6.76% compared to the previous year[4]. - The equity attributable to shareholders of the parent company increased to CNY 4,489,108,733.90 from CNY 4,204,751,036.78 in the previous quarter[25]. Cash Flow - The company reported a net cash flow from operating activities of ¥387,520,537.68, down 50.39% year-on-year[7]. - Operating cash inflow for the current period reached ¥4,341,180,884.13, an increase of 15.7% compared to ¥3,749,602,766.86 in the previous period[41]. - Net cash flow from operating activities decreased to ¥387,520,537.68, down 50.5% from ¥781,191,722.90 in the previous period[41]. - Investment cash inflow totaled ¥1,697,788,655.32, slightly up from ¥1,693,694,743.41 in the previous period[42]. - Net cash flow from investment activities was negative at -¥31,386,127.90, an improvement from -¥591,228,682.28 in the previous period[42]. - Cash flow from financing activities resulted in a net outflow of -¥1,031,083,399.09, worsening from -¥246,516,872.36 in the previous period[42]. - The ending balance of cash and cash equivalents was ¥1,723,559,459.85, compared to ¥1,257,534,070.46 at the end of the previous period[42]. - Total cash outflow for operating activities increased to ¥3,953,660,346.45, up from ¥2,968,411,043.96 in the previous period[41]. - Cash paid for purchasing goods and services rose to ¥1,769,578,575.78, compared to ¥1,268,806,904.53 in the previous period[41]. - Cash paid for taxes increased significantly to ¥542,539,631.27, up from ¥342,636,784.03 in the previous period[41]. - Cash inflow from investment income was ¥26,585,555.32, an increase from ¥20,188,343.41 in the previous period[42]. Strategic Developments - The company completed the acquisition of 100% equity in Hainan Huihai Pharmaceutical, indicating a strategic move for market expansion[31]. - The company plans to continue expanding its market presence and invest in new product development[25]. - The company reported a significant decrease in short-term borrowings, down 97.62% to ¥10,000,000.00 due to repayment of working capital loans[7]. - The company has reduced short-term borrowings significantly from ¥420 million to ¥10 million, indicating improved liquidity management[34]. - The company reported a foreign exchange loss of approximately ¥14.22 million, compared to a loss of ¥23.01 million in the previous period, showing an improvement[26]. - The company reported a credit impairment loss of approximately ¥1.41 million, a recovery from a loss of ¥3.59 million in the previous period[26].